DNANYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Ginkgo Bioworks Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.07−0.20 (-1.95%)
Close on Oct 19, 2026
- Market cap
- $625.29M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$3.18 (−24.00%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Ginkgo Bioworks Holdings, Inc. saw revenue fall 46.8% to $111.86M over the twelve months to Jun 30, 2026. Free cash flow was -$174.80M.
Revenue
$111.86M
-46.8% vs. a year earlier
Operating income
-$290.69M
TTM Q2 2026
Free cash flow
-$174.80M
TTM Q2 2026
EPS, diluted
-$5.00
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $625.29M
- P/E ratio
- –
- Price to sales
- 5.59
- Price to book
- 1.49
- Dividend yield
- –
- Free cash flow yield
- -27.96%
Fundamentals
- Revenue
- $111.86M
- Net income
- -$290.80M
- EPS, diluted
- -$5.00
- Free cash flow
- -$174.80M
- Book value per share
- $6.77
- Diluted shares
- 62M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$111.86M-46.8% YoY
Operating income
-$290.69M
Net income
-$290.80M
EPS, diluted
-$5.00
Free cash flow
-$174.80M
Reported periodTrailing twelve months